Oppliger Leibundgut, Elisabeth

Up a level
Export as [feed] RSS
Group by: Date | Item Type | Refereed | No Grouping
Jump to: 2015 | 2013 | 2012 | 2011 | 2010 | 2009 | 2006 | 1999

2015

Langabeer, Stephen E.; Andrikovics, Hajnalka; Asp, Julia; Bellosillo, Beatriz; Carillo, Serge; Haslam, Karl; Kjaer, Lasse; Lippert, Eric; Mansier, Olivier; Oppliger Leibundgut, Elisabeth; Percy, Melanie J.; Porret, Naomi; Palmqvist, Lars; Schwarz, Jiri; McMullin, Mary F.; Schnittger, Susanne; Pallisgaard, Niels; Hermouet, Sylvie (2015). Molecular diagnostics of myeloproliferative neoplasms. European journal of haematology, 95(4), pp. 270-279. Wiley-Blackwell 10.1111/ejh.12578

Baerlocher, Gabriela M.; Oppliger Leibundgut, Elisabeth; Ottmann, Oliver G; Spitzer, Gary; Odenike, Olatoyosi; McDevitt, Michael A; Röth, Alexander; Daskalakis, Michael; Burington, Bart; Stuart, Monic; Snyder, David S (2015). Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia. The New England journal of medicine, 373(10), pp. 920-928. Massachusetts Medical Society 10.1056/NEJMoa1503479

Saussele, Susanne; Krauss, Marie-Paloma; Hehlmann, Rüdiger; Lauseker, Michael; Proetel, Ulrike; Kalmanti, Lida; Hanfstein, Benjamin; Fabarius, Alice; Kraemer, Doris; Berdel, Wolfgang E; Bentz, Martin; Staib, Peter; de Wit, Maike; Wernli, Martin; Zettl, Florian; Hebart, Holger F; Hahn, Markus; Heymanns, Jochen; Schmidt-Wolf, Ingo; Schmitz, Norbert; ... (2015). Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. Blood, 126(1), pp. 42-49. American Society of Hematology 10.1182/blood-2015-01-617993

Kalmanti, L; Saussele, S; Lauseker, M; Müller, M C; Dietz, C T; Heinrich, L; Hanfstein, B; Proetel, U; Fabarius, A; Krause, S W; Rinaldetti, S; Dengler, J; Falge, C; Oppliger Leibundgut, Elisabeth; Burchert, A; Neubauer, A; Kanz, L; Stegelmann, F; Pfreundschuh, M; Spiekermann, K; ... (2015). Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia, 29(5), pp. 1123-1132. Nature Publishing Group 10.1038/leu.2015.36

Cross, N C P; White, H E; Colomer, D; Ehrencrona, H; Foroni, L; Gottardi, E; Lange, T; Lion, T; Machova Polakova, K; Dulucq, S; Martinelli, G; Oppliger Leibundgut, Elisabeth; Pallisgaard, N; Barbany, G; Sacha, T; Talmaci, R; Izzo, B; Saglio, G; Pane, F; Müller, M C; ... (2015). Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia, 29(5), pp. 999-1003. Nature Publishing Group 10.1038/leu.2015.29

White, H; Deprez, L; Corbisier, P; Hall, V; Lin, F; Mazoua, S; Trapmann, S; Aggerholm, A; Andrikovics, H; Akiki, S; Barbany, G; Boeckx, N; Bench, A; Catherwood, M; Cayuela, J-M; Chudleigh, S; Clench, T; Colomer, D; Daraio, F; Dulucq, S; ... (2015). A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR. Leukemia, 29(2), pp. 369-376. Nature Publishing Group 10.1038/leu.2014.217

Gautschi, O.; Mach, N.; Rothschild, S.; Li, Qiyu; Stahel, R. A.; Zippelius, A.; Cathomas, R.; Früh, M.; Betticher, D. C.; Peters, S.; Rauch, D.; Feilchenfeldt, J.; Bubendorf, L.; Savic, S.; Jaggi, Rolf; Oppliger Leibundgut, Elisabeth; Largiadèr, Carlo Rodolfo; Brutsche, M.; Pilop, C.; Stalder, L.; ... (2015). Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09. Clinical lung cancer, 16(5), pp. 358-365. Elsevier 10.1016/j.cllc.2015.02.007

2013

Jovanovic, J V; Ivey, A; Vannucchi, A M; Lippert, E; Oppliger Leibundgut, Elisabeth; Cassinat, B; Pallisgaard, N; Maroc, N; Hermouet, S; Nickless, G; Guglielmelli, P; van der Reijden, B A; Jansen, J H; Alpermann, T; Schnittger, S; Bench, A; Tobal, K; Wilkins, B; Cuthill, K; McLornan, D; ... (2013). Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study. Leukemia, 27(10), pp. 2032-2039. Nature Publishing Group 10.1038/leu.2013.219

Oppliger Leibundgut, Elisabeth; Porret, Naomi A.; Abbal, Claire; Darbellay, Régis; Goede, Jeroen S.; Kalberer, Christian; Lehmann, Thomas; Baerlocher, Gabriela M. (2013). Molekulares BCR-ABL1-Monitoring bei CML gemäss neuen ELN-Empfehlungen. Internationale Skala in der Schweiz etabliert. Leading opinions - Hämatologie und Onkologie, 4(13), pp. 42-45. Universimed

Helbling, D.; Bodoky, G.; Gautschi, O.; Sun, H.; Bosman, F.; Gloor, Beat; Burkhard, R.; Winterhalder, R.; Madlung, Axel; Rauch, Daniel; Saletti, P.; Widmer, L.; Borner, M.; Baertschi, D.; Yan, P.; Benhattar, J.; Leibundgut, Elisabeth O.; Bougel, S.; Koeberle, D. (2013). Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07. Annals of oncology, 24(3), pp. 718-725. Oxford University Press 10.1093/annonc/mds519

Labarinas, Sonia; Gumy-Pause, Fabienne; Rougemont, Anne-Laure; Baerlocher, Gabriela; Leibundgut, Elisabeth O.; Porret, Naomi; Schäppi, Michela G.; Barazzone-Argiroffo, Constance; Passweg, Jakob; Merlini, Laura; Ozsahin, Hulya; Ansari, Marc (2013). Is Acute Fibrinous and Organizing Pneumonia the Expression of Immune Dysregulation? Journal of pediatric hematology, oncology, 35(2), pp. 139-143. Hagerstown, Md.: Lippincott Williams & Wilkins 10.1097/MPH.0b013e31827e5782

Oppliger Leibundgut, Elisabeth; Porret, Naomi A.; Bienz Muggli, Marianne; Baumgartner, Heidi; Dahlhaus, Meike; Baerlocher, Gabriela M. (2013). Rapid and highly specific screening for NPM1 mutations in acute myeloid leukemia. Annals of hematology, 92(2), pp. 173-177. Berlin: Springer 10.1007/s00277-012-1617-9

Federzoni, Elena A.; Humbert, Magali; Valk, Peter J. M.; Behre, Gerhard; Leibundgut, Elisabeth O.; Torbett, Bruce E; Fey, Martin F.; Tschan, Mario (2013). The actin-binding protein CORO1A is a novel PU.1 (SPI1)- and CEBPA-regulated gene with significantly lower expression in APL and CEBPA-mutated AML patients. British journal of haematology, 160(6), pp. 855-859. Oxford: Wiley-Blackwell 10.1111/bjh.12170

Oppliger Leibundgut, Elisabeth; Baerlocher, Gabriela M. (2013). Molekulare Diagnostik: der Schlüssel zur zielgerichteten Therapie. Schweizerisches Medizin-Forum SMF / Swiss medical forum / Forum médical suisse FMS, 13(1), pp. 8-10. EMH Editores Medicorum Helveticorum

2012

Oppliger Leibundgut, Elisabeth; Rogenmoser-Dissler, Daniela; de Beer, Dirk; Porret, Naomi A; Zibellini, Silvia; Dürig, Jan; Röth, Alexander; Klingbiel, Dirk; Baerlocher, Gabriela M (2012). CLLU1 expression distinguishes chronic lymphocytic leukemia from other mature B-cell neoplasms. Leukemia research, 36(9), pp. 1204-7. Amsterdam: Elsevier 10.1016/j.leukres.2012.05.015

Anderson, Beverley H; Kasher, Paul R; Mayer, Josephine; Szynkiewicz, Marcin; Jenkinson, Emma M; Bhaskar, Sanjeev S; Urquhart, Jill E; Daly, Sarah B; Dickerson, Jonathan E; O'Sullivan, James; Leibundgut, Elisabeth Oppliger; Muter, Joanne; Abdel-Salem, Ghada M H; Babul-Hirji, Riyana; Baxter, Peter; Berger, Andrea; Bonafé, Luisa; Brunstom-Hernandez, Janice E; Buckard, Johannes A; Chitayat, David; ... (2012). Mutations in CTC1, encoding conserved telomere maintenance component 1, cause Coats plus. Nature genetics, 44(3), pp. 338-42. New York, N.Y.: Nature America 10.1038/ng.1084

Zappa, Francesco; Droege, Cornelia; Betticher, Daniel; von Moos, Roger; Bubendorf, Lukas; Ochsenbein, Adrian; Gautschi, Oliver; Oppliger Leibundgut, Elisabeth; Froesch, Patrizia; Stahel, Rolf; Hess, Thomas; Rauch, Daniel; Schmid, Petra; Mayer, Michael; Crowe, Susanne; Brauchli, Peter; Ribi, Karin; Pless, Miklos; on behalf of the Swiss Group for Clinical Cancer Research (SAKK), (2012). Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05). Lung cancer, 78(3), pp. 239-44. Amsterdam: Elsevier 10.1016/S1359-6349(09)71860-9

2011

Humbert, Magali; Halter, Veronika; Shan, Deborah; Laedrach, Judith; Leibundgut, Elisabeth Oppliger; Baerlocher, Gabriela M; Tobler, Andreas; Fey, Martin F; Tschan, Mario P (2011). Deregulated expression of Kruppel-like factors in acute myeloid leukemia. Leukemia research, 35(7), pp. 909-13. Amsterdam: Elsevier 10.1016/j.leukres.2011.03.010

Fontana, Stefano; Rados, Lenka; Schmid, Pirmin; Leibundgut, Elisabeth Oppliger; Taleghani, Behrouz Mansouri (2011). Recruitment of platelets, white blood cells, and hematopoietic progenitor cells during high-yield plateletpheresis. Transfusion, 51(9), pp. 2034-43. Malden, Mass.: Wiley-Blackwell 10.1111/j.1537-2995.2011.03117.x

2010

Tschan, Mario P; Shan, Deborah; Laedrach, Judith; Eyholzer, Marianne; Leibundgut, Elisabeth Oppliger; Baerlocher, Gabriela M; Tobler, Andreas; Stroka, Deborah; Fey, Martin F (2010). NDRG1/2 expression is inhibited in primary acute myeloid leukemia. Leukemia research, 34(3), pp. 393-8. Amsterdam: Elsevier 10.1016/j.leukres.2009.08.037

Baerlocher, Gabriela M; Oppliger Leibundgut, Elisabeth (2010). [Molecular analyses for (early) recognition of hematologic diseases - sense and sensibility for molecular analysis: the art of intelligent decision-making]. Therapeutische Umschau, 67(7), pp. 349-58. Bern: Huber

2009

Wampfler, Julian; Tschan, Mario P; Shan, Deborah; Laemmle, Alexander; Leibundgut, Elisabeth O; Baerlocher, Gabriela M; Stroka, Deborah; Fey, Martin F; Britschgi, Christian (2009). SIRT1 is downregulated during neutrophil differentiation of acute promyelocytic leukaemia cells. British journal of haematology, 146(3), pp. 337-41. Oxford: Wiley-Blackwell 10.1111/j.1365-2141.2009.07749.x

2006

Mueller, B U; Buerger, A U; Solenthaler, M; Garamvoelgyi, E M; Oppliger-Leibundgut, E; Fey, M F; Pabst, T (2006). Pleural tumors as sole primary manifestation of acute promyelocytic leukemia. Annals of oncology, 17(4), pp. 722-3. Oxford: Oxford University Press 10.1093/annonc/mdj062

Oppliger Leibundgut, Elisabeth; Horn, Michael Peter; Brunold, Claudio; Pfanner-Meyer, Brigitte; Marti, Dorothee; Hirsiger, Hans; Tobler, Andreas; Zwicky, Caroline (2006). Hematopoietic and endothelial progenitor cell trafficking in patients with myeloproliferative diseases. Haematologica - the hematology journal, 91(11), pp. 1465-72. Pavia: Ferrata-Storti Foundation

1999

Peters, Uwe R; Hasse, Urs; Oppliger Leibundgut, Elisabeth; Tschan, Mario; Ong, S Tiong; Rassool, Feyruz V; Borisch, Bettina; Tobler, Andreas; Fey, Martin (1999). Aberrant FHIT mRNA transcripts are present in malignant and normal haematopoiesis, but absence of FHIT protein is restricted to leukaemia. Oncogene, 18(1), pp. 79-85. Nature Publishing Group 10.1038/sj.onc.1202256

Provide Feedback